vs
Side-by-side financial comparison of Albertsons Companies, Inc. (ACI) and Merck & Co. (MRK). Click either name above to swap in a different company.
Albertsons Companies, Inc. is the larger business by last-quarter revenue ($19.1B vs $16.4B, roughly 1.2× Merck & Co.). Merck & Co. runs the higher net margin — 18.1% vs 1.5%, a 16.5% gap on every dollar of revenue. On growth, Merck & Co. posted the faster year-over-year revenue change (5.0% vs 1.9%). Merck & Co. produced more free cash flow last quarter ($1.8B vs $-94.7M). Over the past eight quarters, Albertsons Companies, Inc.'s revenue compounded faster (3.3% CAGR vs 2.0%).
Albertsons Companies, Inc. is an American grocery company founded and headquartered in Boise, Idaho.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
ACI vs MRK — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1B | $16.4B |
| Net Profit | $293.3M | $3.0B |
| Gross Margin | 27.4% | 66.2% |
| Operating Margin | 2.6% | 20.9% |
| Net Margin | 1.5% | 18.1% |
| Revenue YoY | 1.9% | 5.0% |
| Net Profit YoY | -26.8% | -20.8% |
| EPS (diluted) | $0.55 | $1.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.1B | $16.4B | ||
| Q3 25 | — | $17.3B | ||
| Q2 25 | $24.9B | $15.8B | ||
| Q1 25 | $18.8B | $15.5B | ||
| Q4 24 | $18.8B | $15.6B | ||
| Q3 24 | — | $16.7B | ||
| Q2 24 | $24.3B | $16.1B | ||
| Q1 24 | — | $15.8B |
| Q4 25 | $293.3M | $3.0B | ||
| Q3 25 | — | $5.8B | ||
| Q2 25 | $236.4M | $4.4B | ||
| Q1 25 | $171.8M | $5.1B | ||
| Q4 24 | $400.6M | $3.7B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | $240.7M | $5.5B | ||
| Q1 24 | — | $4.8B |
| Q4 25 | 27.4% | 66.2% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | 27.1% | 77.5% | ||
| Q1 25 | 27.4% | 78.0% | ||
| Q4 24 | 27.9% | 75.5% | ||
| Q3 24 | — | 75.5% | ||
| Q2 24 | 27.8% | 76.8% | ||
| Q1 24 | — | 77.6% |
| Q4 25 | 2.6% | 20.9% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | 1.8% | 31.6% | ||
| Q1 25 | 1.5% | 38.0% | ||
| Q4 24 | 2.8% | 26.7% | ||
| Q3 24 | — | 24.6% | ||
| Q2 24 | 1.9% | 37.3% | ||
| Q1 24 | — | 35.9% |
| Q4 25 | 1.5% | 18.1% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | 1.0% | 28.0% | ||
| Q1 25 | 0.9% | 32.7% | ||
| Q4 24 | 2.1% | 24.0% | ||
| Q3 24 | — | 19.0% | ||
| Q2 24 | 1.0% | 33.9% | ||
| Q1 24 | — | 30.2% |
| Q4 25 | $0.55 | $1.19 | ||
| Q3 25 | — | $2.32 | ||
| Q2 25 | $0.41 | $1.76 | ||
| Q1 25 | $0.29 | $2.01 | ||
| Q4 24 | $0.69 | $1.49 | ||
| Q3 24 | — | $1.24 | ||
| Q2 24 | $0.41 | $2.14 | ||
| Q1 24 | — | $1.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.1M | $14.6B |
| Total DebtLower is stronger | $8.4B | — |
| Stockholders' EquityBook value | $2.5B | $52.6B |
| Total Assets | $27.1B | $136.9B |
| Debt / EquityLower = less leverage | 3.36× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $195.1M | $14.6B | ||
| Q3 25 | — | $18.2B | ||
| Q2 25 | $151.0M | $8.6B | ||
| Q1 25 | $293.6M | $9.2B | ||
| Q4 24 | $202.3M | $13.7B | ||
| Q3 24 | — | $14.6B | ||
| Q2 24 | $291.1M | $11.4B | ||
| Q1 24 | — | $5.6B |
| Q4 25 | $8.4B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.0B | — | ||
| Q1 25 | $7.8B | — | ||
| Q4 24 | $7.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $7.8B | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.5B | $52.6B | ||
| Q3 25 | — | $51.9B | ||
| Q2 25 | $3.2B | $49.0B | ||
| Q1 25 | $3.4B | $48.3B | ||
| Q4 24 | $3.4B | $46.3B | ||
| Q3 24 | — | $44.5B | ||
| Q2 24 | $2.9B | $43.6B | ||
| Q1 24 | — | $40.4B |
| Q4 25 | $27.1B | $136.9B | ||
| Q3 25 | — | $129.5B | ||
| Q2 25 | $26.5B | $117.5B | ||
| Q1 25 | $26.8B | $115.1B | ||
| Q4 24 | $26.7B | $117.1B | ||
| Q3 24 | — | $117.5B | ||
| Q2 24 | $26.1B | $112.6B | ||
| Q1 24 | — | $105.8B |
| Q4 25 | 3.36× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.17× | — | ||
| Q1 25 | 2.29× | — | ||
| Q4 24 | 2.31× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.67× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $367.6M | $2.9B |
| Free Cash FlowOCF − Capex | $-94.7M | $1.8B |
| FCF MarginFCF / Revenue | -0.5% | 11.1% |
| Capex IntensityCapex / Revenue | 2.4% | 6.3% |
| Cash ConversionOCF / Net Profit | 1.25× | 0.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $367.6M | $2.9B | ||
| Q3 25 | — | $7.8B | ||
| Q2 25 | $754.4M | $3.3B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $548.0M | $3.5B | ||
| Q3 24 | — | $9.3B | ||
| Q2 24 | $960.9M | $5.6B | ||
| Q1 24 | — | $3.1B |
| Q4 25 | $-94.7M | $1.8B | ||
| Q3 25 | — | $6.8B | ||
| Q2 25 | $169.8M | $2.5B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $53.6M | $2.5B | ||
| Q3 24 | — | $8.5B | ||
| Q2 24 | $417.9M | $4.8B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | -0.5% | 11.1% | ||
| Q3 25 | — | 39.6% | ||
| Q2 25 | 0.7% | 16.0% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | 0.3% | 16.1% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | 1.7% | 30.1% | ||
| Q1 24 | — | 14.1% |
| Q4 25 | 2.4% | 6.3% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | 2.3% | 4.8% | ||
| Q1 25 | — | 8.6% | ||
| Q4 24 | 2.6% | 6.0% | ||
| Q3 24 | — | 4.7% | ||
| Q2 24 | 2.2% | 4.9% | ||
| Q1 24 | — | 5.5% |
| Q4 25 | 1.25× | 0.96× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | 3.19× | 0.74× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | 1.37× | 0.92× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | 3.99× | 1.03× | ||
| Q1 24 | — | 0.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACI
| Retail Sales | $18.9B | 99% |
| Third Party Sales And Other Miscellaneous Revenue | $196.8M | 1% |
MRK
| Pharmaceuticalsegment | $8.7B | 53% |
| Keytruda | $4.9B | 30% |
| Other | $2.7B | 16% |
| Janumet | $57.0M | 0% |
| Isentress Isentress HD | $38.0M | 0% |
| Pifeltro | $25.0M | 0% |
| Belsomra | $23.0M | 0% |
| Dificid | $17.0M | 0% |
| Delstrigo | $14.0M | 0% |
| Lagevrio | $12.0M | 0% |
| Pneumovax23 | $4.0M | 0% |
